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Objective: To identify and summarise 1) appraisal tools and other guides which address 
conflicts of interest in medical research studies; and 2) top journals with policies on 
managing conflicts of interest in journal papers. 
Study Design and Setting: Systematic review. We searched bibliographic databases, 
other sources and websites of 30 top medical journals. Two authors selected documents 
and extracted data. 
Results: We included 27 appraisal tools. None were designed specifically for addressing 
conflicts of interest and they included only 1-2 short items on conflicts of interest. We also 
included eight other types of guides. Of 27 appraisal tools, 23 addressed study funding 
and 19 authors’ conflicts of interest. Nine tools addressed availability of conflicts of interest 
information, 13 reported conflicts of interest, and five influence from conflicts of interest. 
Twelve of 30 top journals had conflicts of interest managing policies (beyond disclosure). 
One journal restricted non-research papers (e.g. editorials) to authors without financial 
conflicts of interest and ten only restricted under certain circumstances.  
Conclusion: Appraisal tools that address conflicts of interest typically do so superficially 
and rarely address how conflicts of interest may influence studies. Less than half of top 
medical journals have explicit policies on managing conflicts of interest.  
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What is new? 
 
Key findings 
•  We identified no appraisal tool designed specifically to address conflicts of interests 
in medical research studies. Twenty-seven tools included 1-2 short items mainly 
focusing on whether conflicts of interest information was available or if any conflicts 
of interest were reported. There was little guidance on assessing how conflicts of 
interest may influence studies.  
•  In a small sample of 30 top medical journals more than half had no explicit policies 
on managing conflicts of interest in journal papers beyond standard disclosure 
practices. Journals with policies to manage conflicts of interest mainly placed some 
form of restriction on non-research papers, publishing only those where authors did 
not have financial conflicts of interest.  
 
What this adds to what is known? 
•  Conflicts of interest are considered important, but the focus in both appraisal tools 
and journals is on how conflicts of interest are disclosed; not on how conflicts of 
interest may influence studies or how journal policies may minimise such influence. 
 
What is the implication, what should change now? 
•  There is need for more comprehensive evidence-based guidance for addressing 
conflicts of interest in research studies. 
•  The International Committee of Medical Journal Editors and medical journals could 
consider developing, revising and harmonising explicit policies on managing 




More than half of medical research funding originates from the drug and device industry [1] 
and around two-third of drug trials are industry-funded [2–4]. Similarly, more than half of 
clinical trials include investigators with financial ties to companies producing interventions 
tested in the trials [2,3]. Such relationships create conflicts of interest and introduce a risk 
that the primary scientific interest of an impartial investigation may be compromised by 
secondary commercial interests [5]. Similarly, specialist interests and academic 
relationships may create non-financial conflicts of interest [4,6].  
While it is generally agreed that conflicts of interest pose an important threat to the 
integrity of science, it has been much debated how to tackle the problem [5,7]. Currently 
most medical journals request that authors report sources of study funding transparently 
and disclose any relationships that may be perceived as conflicts. Readers are then left to 
assess whether and to what degree such conflicts of interests could have influenced study 
findings. This assessment is often a challenge, when reading a single research paper, 
when reading several papers to guide a clinical decision, or when critically appraising 
multiple studies in the context of developing a clinical practice guideline or conducting a 
systematic review [8,9]. While numerous tools are available for appraising research 
studies of different designs [10–12] they seem to address conflicts of interest differently. 
Another journal strategy is to manage conflicts of interest by restricting publication of 
journal papers to authors without conflicts of interest. The majority of medical journals 
require transparently reporting funding source and authors’ conflicts of interest using the 
International Committee Medical Journal Editors’ (ICMJE) criteria [13], but little is known 
on how journals manage conflicts of interest beyond disclosure.  
We therefore undertook a systematic review to identify and summarise 1) appraisal tools 
and other guides which address conflicts of interest of funders and authors in medical 
research studies; and 2) top medical journals with policies on managing conflicts of 
interest in journal papers.  
 
2. Methods 
2.1 Protocol and registration 
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A protocol was written and registered prior to study conduct (August 3, 2017; PROSPERO 
record: CRD42017070208). 
 
2.2 Eligibility criteria – appraisal tools and other guides 
We included appraisal tools and other guides, in any language, which address conflicts of 
interest in any type of medical research study. This included methodological checklists 
with items related to conflicts of interest, other guides such as handbooks for conducting 
systematic reviews which contained specific recommendations for addressing conflicts of 
interest in included studies, and journal guidance for assisting peer reviewers. We 
excluded reporting guidelines, and appraisal tools and other guides which address 
conflicts of interest in clinical practice guidelines (Appendix 1).  
We used the Institute of Medicine conflicts of interest definition: “a set of circumstances 
that creates a risk that professional judgment or actions regarding a primary interest will be 
unduly influenced by a secondary interest” [5]. This included financial conflicts of interest 
(e.g. study funding or authors’ ties) and non-financial conflicts of interest (e.g. specialist or 
academic conflicts of interest) [6,14]. 
 
2.3 Eligibility criteria – journals  
We included medical journals with policies on managing conflicts of interest among 
funders and authors of journal papers that went beyond simple disclosure. This included 
restrictions on publishing studies related to specific funding sources (e.g. not permitting 
funding by tobacco companies) or conflicts of interest related to certain types of papers 
(e.g. only publishing editorials by authors without financial conflicts of interest).  
We excluded journals with policies that focused only on managing conflicts of interest 
among editors or peer reviewers. 
 
2.4 Search strategy 
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We searched MEDLINE and Embase via Ovid and the Cochrane Methodology Register 
(up to November 1, 2017), and Google Scholar (in November 2017). The search strategy 
was developed for MEDLINE and adapted for the other databases (Appendix 2).  
We searched the websites of the EQUATOR Network, and Cochrane including all review 
groups. Furthermore, we searched the reference lists of included documents and relevant 
systematic reviews, and searched Web of Science for any studies citing the included 
documents (in August 2018). We contacted 20 content experts (in December 2018) and 
searched for relevant unpublished conference abstracts from previous Cochrane 
Colloquia, Evidence Live and the Congress on Peer review and Scientific Publication (in 
August 2018).  
We searched the websites of 30 top medical journals (10 general medical journals and 20 
specialty journals with the highest impact factors) for any guides for peer reviewers and 
journal policies on managing conflicts of interests (Appendix 3). In our study we describe 
this sample of journals as top journals and other journals as regular journals. We 
contacted the journals to ensure that relevant guides and policies were identified (20 of 30 
journals replied after one email and two reminders). 
 
2.5 Inclusion process 
One author (LØ) screened titles and abstracts (i.e. publications or website information) for 
obvious exclusions. In a second round two authors (LØ and KR) independently assessed 
full text documents and disagreements were resolved through discussion with a third 
author (AL) as arbiter.  
 
2.6 Data extraction 
One author (AL) extracted data into a pilot tested and standardised data sheet with 
verification by a second author (KR).  
We extracted general characteristics of documents, how they were developed and how 
conflicts of interest were addressed (Appendix 1). We defined appraisal tools using a 
modification of Higgins and colleagues [11], as any structured instrument aimed at aiding 
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the user to assess quality or susceptibility to bias in research studies or to assess the 
quality of the body of evidence based on a synthesis of studies. For other guides we 
divided them into: 1) guidance questions: any list of guidance questions aimed at assisting 
readers in appraising a study, that did not contain specific categories for answers (such as 
yes, no and unclear); and 2) set of recommendations: documents providing readers with 
recommendations which did not fit the definition of the categories above (e.g. handbooks 
for conducting systematic reviews).  
For appraisal tools we extracted additional information on tool development and divided 
them into groups: simple checklist, checklist with overall rating and scale (i.e. containing 
summary numerical scores typically derived from scores of individual items). We used a 
hierarchical approach to describe how conflicts of interest were addressed in each tool 
based on the categories: 1) availability of conflicts of interest information (i.e. assessment 
of whether study publication contained disclosure statements); 2) reported conflicts of 
interest (i.e. assessment of whether any conflicts of interest were reported in the study); 
and 3) influence from conflicts of interest (e.g. assessment of whether a study included 
procedural elements minimising influence from conflicts of interest or if certain types of 
conflicts of interest were judged to have a higher risk of influencing study results).  
 
2.7 Usage of appraisal tools with items addressing conflicts of interest 
For published appraisal tools we noted the total number of citations, and citations since 
2018, of the main tool publication using Google Scholar (May 8, 2019).  
 
3. Results 
In total, we included 27 appraisal tools [12,15-35], eight other types of guides which 
address conflicts of interest [36–43] and 14 journals (12 top journals and two regular 
journals from our database search) (Figure 1). Of the eight other types of guides three 
were journal papers with specific guidance questions for journal readers to be used when 
appraising research papers [36–38] and five were guides which addressed conflicts of 
interest in the context of conducting systematic reviews [39–43]. To enhance readability, 
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we focus on the content of appraisal tools in the main text, and report the content of the 
other guides in the appendix (Appendix 1 and 4-7).  
 
3.1 Appraisal tools with items addressing conflicts of interest 
Eighteen tools were designed to appraise primary research studies of various design, 
seven tools to appraise systematic reviews and two tools to rate the quality of the body of 
evidence. None had been developed specifically to address conflicts of interest (Table 1; 
Appendix 1 and 8). The tools were published from 1989 to 2017 (median: 2014) and 
included from 7 to 56 items (median: 13). 
The proportion of tool items related to conflicts of interest ranged from 1 in 5 items to 1 in 
43 items (Table 2; Appendix 9). Twenty-three tools addressed study funding source and 
19 addressed authors’ conflicts of interest. Nine tools included assessment of whether 
conflict of interest information was available for a study, 13 assessed whether any conflicts 
of interest were reported in a study and five assessed whether conflicts of interest might 
have influenced study results or interpretation. Seven tools described conflicts of interest 
as a separate type of bias. Six of 27 tools were developed using systematic methods (i.e. 
based on a literature search, used a defined process, and were both pilot and reliability 
tested). 
The five tools addressing influence from conflicts of interest did so differently. Three tools, 
AMSTAR 2 and DART for systematic reviews, and PQAQ for paediatric health economic 
studies, focused on management of conflicts of interest with different criteria for what was 
considered appropriate methodology [15,19,29]. The AMSTAR 2 tool required a 
description of how the conflicts of interest were managed and the DART tool required 
exclusion of individuals with substantial conflicts of interest from study involvement, though 
without describing a threshold. The PQAQ tool had one item requiring that the role of the 
sponsor should be explicitly stated and another item requiring study authors to have had 
independent control over the methods and right to publish, but did not take conflicts of 
interest of study authors into account. Two tools, IPM-QRB and IPM-QRBNR for trials and 
observational studies of pain management interventions, focused on judging the degree of 
conflicts of interest [24,25]. Both tools used a scale approach assigning negative scores if, 
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for example, industry employees were involved or if conflicts of interest disclosure 
information was misleading.  
 
3.2 Usage of appraisal tools with items addressing conflicts of interest 
GRADE, AMSTAR and AMSTAR 2 were the three most cited appraisal tools both in total 
and since 2018 (Figure 2; Appendix 10).  
 
3.3 Journals with policies on managing conflicts of interest 
Five of 12 top journals with policies on managing conflicts of interest were general medical 
journals and seven were specialty journals. Six of these 12 top journals were from the 
Lancet group (Table 3; Appendix 11).  
One top journal, BMJ, restricted publication of non-research papers (e.g. editorials) to 
authors without financial conflicts of interest and ten top journals restricted it to authors 
without certain types of financial conflicts of interest. For two of these ten journals this was 
based on editorial judgement (CMAJ and PLoS Medicine), for one journal it was based on 
a certain monetary threshold (NEJM) and for the last seven journals it was based on 
specific types of financial conflicts of interest (Blood and the six Lancet journals). Three 
journals, American Journal of Critical Care and Respiratory Medicine, BMJ and PLoS 
Medicine, did not permit publication of any study with funding from the tobacco industry.  
None of the identified top journals had conflicts of interest managing policies in research 
papers or addressed non-financial conflicts of interest. However, one regular journal, 
Cochrane Database of Systematic Reviews, did not permit commercial funding of any 
research paper, required that the majority of authors should be without financial conflicts of 
interest and that editors should check data if a review included studies by review authors.  
 
4. Discussion 
We identified no tools developed specifically for addressing conflicts of interest, and 27 
general appraisal tools including 1-2 short items addressing conflicts of interest, and 8 
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other guides. No tools addressed conflicts of interest comprehensively as they mainly 
focused on whether conflicts of interest information was available or any conflicts of 
interest were reported and provided little guidance on assessing how they might influence 
studies. Less than half of top journals had explicit policies on managing conflicts of interest 
beyond disclosure, e.g. restricting publication of non-research papers to authors without 
financial conflicts of interest.  
  
4.1 Strengths and weaknesses 
We undertook a comprehensive literature search. However, as we found that some 
specific tools were developed as part of an evaluation of a sample of studies and not 
described in the abstract and some tools were only available on websites [18,28,32] we 
might therefore have missed relevant tools and other guides. We investigated only a small 
sample of top journals with policies on managing conflicts of interest and half of top 
journals with policies were from the Lancet group. This may limit the generalisability of our 
findings particular in relation to low impact medical journals. 
 
4.2 Context 
This is to our knowledge the first study to specifically investigate how conflicts of interest 
are addressed in appraisal tools and other guides. A previous systematic review of 
epidemiological appraisal tools reported that three of 86 tools included items addressing 
conflicts of interest [11]. A more recent systematic review reported this to be the case for 
seven of 62 tools for human epidemiological studies [44]. Similar to our study the tools 
included in the systematic reviews varied in relation to how and for which context they 
were developed. However, none of the systematic reviews investigated how conflicts of 
interest were addressed in the included appraisal tools.  
We found that tools used variable approaches to address conflicts of interest, likely 
reflecting a lack of consensus on how best to handle conflicts of interest in medical 
research. Industry funding and authors’ financial ties have been associated with more 
frequent reporting of statistically significant results and favourable conclusions in trials 
[2,45], and also more favourable conclusions in systematic reviews [46]. However, it has 
11 
 
been debated whether this association should be interpreted as conflicts of interest being 
an independent bias-inducing mechanism or if conflicts of interest should be viewed as a 
proxy for underlying differences in study characteristics, such as more frequent use of 
inferior comparators and surrogate outcomes in industry trials compared with non-industry 
trials [47–49]. Seven of the tools we reviewed described conflicts of interest as a separate 
type of bias and one study found that 28% of Cochrane Reviews included conflicts of 
interest in the risk of bias assessment despite the Cochrane Handbook advocating against 
this practice [49,50]. This recommendation has been debated within Cochrane [47,48] and 
the recent version of the Cochrane Handbook now propose that in addition to reporting 
trial conflicts of interest review authors should also assess conflicts of interest as part of 
study appraisal, though without considering it as a separate type of bias [51]. 
In relation to journals with conflicts of interest managing policies Bero surveyed 10 top 
general medical journals and found results similar to ours [52]. However, our study also 
extends to top specialty journals. Only two of 15 top specialty journals that did not belong 
to the Lancet group had policies to manage conflicts of interest. This could suggest that 
such policies are adopted less frequently in top specialty journals compared to top general 
medical journals, but our sample is too small to make a robust comparison.   
 
4.3 Implications 
Most tools focused on whether conflicts of interest information was available or if any 
conflicts of interest were reported. These approaches do not take into account the degree 
of conflicts of interest (e.g. a trial sponsored by a drug company compared to a trial where 
one investigator had received a single sponsored conference trip) or the potential influence 
from collaborators with conflicts of interest (e.g. an industry-initiated trial run by the 
company compared to an investigator-initiated trial with industry funding, but run by a 
university based clinical trial unit).  
Only five tools addressed whether conflicts of interest might have influenced study results 
or interpretation either by focusing on whether conflicts of interest were managed in some 
form, or by focusing on the degree of conflicts of interest in a study. The AMSTAR 2 tool 
(for assessing quality of systematic reviews) addressed whether conflicts of interest were 
managed thereby addressing conflicts of interest in a more comprehensive manner. 
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However, the tool provided no assessment as to whether conflicts of interest were 
managed in an adequate way. Similarly, while the four other tools addressing influence 
from conflicts of interest (DART, IPM-QRB, IPM-QRBNR and PQAQ) did so in a more 
detailed manner compared to other tools, they did not provide adequate assessment to 
how conflicts of interest might have influenced a study. 
There is therefore a need for a tool aimed at addressing conflicts of interest in a more 
detailed manner and developed using evidence-based principles. One way forward could 
be the Tool for Addressing Conflicts of Interest in Trials (TACIT) which is currently in 
development under the auspices of the Cochrane Bias Methods Group [51,53,54]. The tool 
aims at judging concern for conflicts of interest in trials included in systematic reviews and 
works in conjunction with other review tools such as Risk of Bias 2, Risk of Bias due to 
Missing Evidence and GRADE [22,55,56] and TACIT may stimulate the development of 
appraisal tools aimed at other study designs.  
Our results also highlight a striking contrast between the importance given to conflicts of 
interest by medical journals and how journals currently address and manage such conflicts 
of interest. As an example, we did not identify any guidance for peer reviewers for 
addressing conflicts of interest in research papers. Furthermore, while there has been a 
move towards managing conflicts of interest in clinical guidelines with major guidelines 
issuing organisations such as US Preventive Services Task Force, WHO and NICE having 
policies excluding or limiting the role of authors with certain types of conflicts of interest 
[57–59] this is not the case for research papers in top medical journals.  
Journals may be reluctant to introduce restrictive conflicts of interest policies for research 
papers as it may be commercially disadvantageous due to loss of revenue from reprint 
sales and lowering of impact factors [60,61]. One solution could be to introduce future 
policies across multiple journals simultaneously, for example at the level of publishers or 
under the auspices of ICMJE. Such policies should also address conflicts of interest of 
editors and peer reviewers as they may similarly influence the content of papers published 





We identified no tools that specifically addressed conflicts of interest, and 27 general 
appraisal tools addressed conflicts of interest in 1-2 short items. No tools addressed 
conflicts of interest comprehensively as they mainly focused on whether conflicts of 
interest information was available or if any conflicts of interest were reported and offered 
little practical guidance to users on assessing how conflicts of interest might influence 
studies. Less than half of our small sample of top journals had explicit policies on 
managing conflicts of interest beyond disclosure, most often restricting non-research 
papers to authors without financial conflicts of interest. There seems to be a striking 
contrast between the considerable attention given to conflicts of interest in medical 
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Table 1. Characteristics of 27 appraisal tools with items on conflicts of interest 
  
Appraisal tool characteristics  
 
All tools 
(n = 27) 
 
Tools intended for appraising 
Primary research  
(n = 18) 
Systematic reviews  
(n = 7) 
Body of evidence  
(n = 2) 
 Number (percentages)* 
 
Items related to conflicts of interest included in appraisal tool     
     1 item       20 (74%) 14 (78%) 6 (86%) 0 (0%) 
     2 items 4 (15%) 3 (17%) 1 (14%) 0 (0%) 
    No separate item (addressed as part of another item) 3 (11%)  1 (6%) 0 (0%) 2 (100%) 
Content of items related to conflicts of interest     
     addressed study funding 23 (85%) 15 (83%) 6 (86%) 2 (100%) 
     addressed author conflicts of interest 19 (70%) 13 (72%) 4 (57%) 2 (100%) 
     considered conflicts of interest as a separate type of bias 7 (26%) 6 (33%) 1 (14%) 0 (0%) 
Appraisal tool identified from     
     Journal publication 24 (89%) 17 (94%) 6 (86%) 1 (50%) 
     Website 3 (11%) 1 (6%) 1 (14%) 1 (50%) 
Appraisal tool developed using systematic methods** 6 (22%) 3 (17%) 2 (29%) 1 (50%) 
Type of appraisal tool     
     Simple checklist 7 (26%) 5 (28%) 2 (29%) 0 (0%) 
     Checklist with overall rating 15 (56%) 9 (50%) 4 (57%) 2 (100%) 
     Scale 5 (19%) 4 (22%) 1 (14%) 0 (0%) 
Quality issues addressed in appraisal tool     
     Generalisability  10 (37%) 7 (39%) 1 (14%) 2 (100%) 
     Methodological   27 (100%) 18 (100%) 7 (100%) 2 (100%) 
     Reporting    21 (78%) 14 (78%) 7 (100%) 0 (0%) 
     Statistics 23 (85%) 14 (78%) 7 (100%) 2 (100%) 
*Percentages do not always add up to 100 due to rounding. 
** If tool was developed based on a literature search, using a defined process, and both pilot and reliability tested. 







Number of items on 
conflicts of interest/ 
total number of items 
 
Addressed 







How conflicts of interest  
were addressed  
 
Conflicts of interest 
described as a separate 
type of bias 
 
Primary research tools  
     
AXIS 1/20 Yes Yes Reported conflicts of interest No 
Berra 1/27 Yes Yes Reported conflicts of interest No 
Cochrane Hepato-Biliary Group 1/8 Yes No Reported conflicts of interest Yes 
Cowley-case series 1/17 No Yes Reported conflicts of interest No 
Cowley-non-randomised studies 1/13 No Yes Reported conflicts of interest No 
Cowley-RCT 1/12 No Yes Reported conflicts of interest No 
Faillie 2/10-32
**
 Yes Yes Reported conflicts of interest Yes 
Guo 1/20 Yes Yes Availability of conflicts of interest information No 
IPM-QRB 2/22 Yes Yes Influence from conflicts of interest No 
IPM-QRBNR 1/16 Yes No Influence from conflicts of interest No 
Moncrieff 1/23 Yes Yes Availability of conflicts of interest information No 
Navigation Guide-human 1/8 Yes Yes Availability of conflicts of interest information Yes 
Navigation Guide-non-human 1/7 Yes Yes Availability of conflicts of interest information Yes 
PQAQ 2/56 Yes No Influence from conflicts of interest No 
QCC-non human 1/10 Yes Yes Reported conflicts of interest Yes 
QCC-primary research 1/10 Yes Yes Reported conflicts of interest Yes 
Reisch 0/12
****
 Yes No Availability of conflicts of interest information No 
Viswanathan 1/29 Yes No Availability of conflicts of interest information No 
 
Systematic review tools 
     
AMSTAR 1/11 Yes No Availability of conflicts of interest information No 
AMSTAR 2 2/16 Yes Yes Influence from conflicts of interest No 
DART 1/14 No Yes Influence from conflicts of interest No 
Higgins 1/43 Yes No Availability of conflicts of interest information No 
QCC-reviews 1/10 Yes No Reported conflicts of interest Yes 
R-AMSTAR 1/11 Yes Yes Reported conflicts of interest No 
SIGN 1/13 Yes Yes Availability of conflicts of interest information No 
      
 
Body of evidence tools 
     
GRADE 0/8
***
 Yes Yes Reported conflicts of interest No 
OHAT 0/10
***
 Yes Yes Reported conflicts of interest No 
* If tool did not have an official short or abbreviated name we used the name of the first author of the main publication. 
** Tool intended for appraisal of RCTs, cohort studies, case-control studies and systematic reviews with some items tailored for specific study designs. Considered to be a single tool. 
*** Indirectly included conflicts of interest in an item on publication bias. 
**** Conflicts of interest addressed in one of five subquestion in an item on purpose of study. 
 






Description of management 





















Does not publish any paper funded by tobacco companies or by authors with 
relationships with tobacco companies. Corresponding authors must have full 
access to data and take responsibility for integrity of data if study is commercially 
funded. 
Yes Yes Yes Partly** Relevant 
industries 
No 
Blood Authors with pharmaceutical or medical device company employment and medical 
writers supported by these industries must not have any role in writing Review, 
Perspective, How I Treat, Blood Spotlight, or Evidence-based Focused Review 
articles. 
Partly*** Yes No Yes Drug and 
device 
No 
BMJ Does not permit authors with relevant financial ties to drug, device, test, medical 
education or other relevant industries for writing editorials, clinical reviews, 
minerva pictures, endgames and practice articles. Prohibits any study that is partly 
or wholly funded by the tobacco industry. 
Yes Yes Yes Partly** Relevant 
industries  
No 
CMAJ Editor may exclude authors with financial conflicts of interest or industry 
employment from writing commentaries and narrative reviews. 
No Yes Yes Yes Relevant 
industries 
No 
Lancet Does not permit authors with relevant employment or certain types of financial 
conflicts of interest for writing Comment, Seminars, Reviews, and Series articles. 
No Yes Yes Yes Relevant 
industries 
No 
Lancet Diabetes & 
Endocrinology 
Does not permit authors with relevant employment or certain types of financial 
conflicts of interest for writing Comment, Seminars, Reviews, and Series articles. 
No Yes Yes Yes Relevant 
industries 
No 
Lancet  Infectious 
Diseases 
Does not permit authors with relevant employment or certain types of financial 
conflicts of interest for writing Comment, Seminars, Reviews, and Series articles. 
No Yes Yes Yes Relevant 
industries 
No 
Lancet Neurology Does not permit authors with relevant employment or certain types of financial 
conflicts of interest for writing Comment, Seminars, Reviews, and Series articles. 
No Yes Yes Yes Relevant 
industries 
No 
Lancet Oncology Does not permit authors with relevant employment or certain types of financial 
conflicts of interest for writing Comment, Seminars, Reviews, and Series articles. 





Does not permit authors with relevant employment or certain types of financial 
conflicts of interest for writing Comment, Seminars, Reviews, and Series articles. 




Journal of Medicine 
Does not permit authors with significant financial interests (i.e. > 10.000 US $ or 
stock or patents) for writing editorials and review articles. 
No Yes Yes Yes Relevant 
industries 
No 
PLoS Medicine Does not publish any paper with any degree of funding of research costs or 
authors' salaries by a tobacco company. Does not permit commissioned or other 
non-research articles by authors with conflicts of interest which according to 
editors could introduce bias or reasonable perception of bias. 




* By author conflicts of interest we mean any conflicts of interest in addition to direct employment (e.g. advisory board membership). 
** Any type of publication in relation to tobacco funding, but specific types of publications in relation to other conflicts of interest. 
*** Indirectly by prohibiting industry funding of medical writers. 
 
Figure 1. Study flow diagram of inclusion process 
 
Screening of unique 
records identified from 
database search: 7284  
Screening of websites of 





assessed for eligibility: 32 
Records excluded: 7252 
Documents included: 32* 
Documents excluded: 16 
14 Did not address conflicts of interest 
2 Reporting guidelines 
Top journals without conflicts of 
interest managing policies: 18 
Journals with conflicts of 
interest managing policies 
identified: 12 2 journals 35 guides 
Guides included: 35 
27 appraisal tools  
8 other types of guides 
*Some documents contained more than one guide 
Journals identified: 14 
12 top journals 
2 regular journals 
Figure 2. Total number of citations of appraisal tools with items addressing conflicts 
of interest 
 
* Some tools were available in formats tailored for specific study designs, but described in same publication. For these 
tools we reported citations to the overall tool publication. 
** GRADE was described in multiple publications and we reported citations for the publication related to conflicts of 









Figure 3. Examples of how conflicts of interest were addressed in appraisal tool 
items 






Name of Tool 
  
 
Item on conflicts of interest 
AMSTAR Was the conflict of interest stated? 
  










Name of Tool  
 
 
Item on conflicts of interest 
Cowley-RCT   Independence of investigators (no vested interest) stated 
 
QCC-Primary Research  
 
Is bias due to study’s funding or sponsorship unlikely? 
 - were sources of funding and investigators’ affiliations described? 
 - was there no apparent conflict of interest? 
  
  





Name of Tool  
 
 
Item on conflicts of interest 
DART  Were conflicts of interest stated and were individuals excluded from 
the review if they reported substantial financial and intellectual 
conflicts of interest? 
  
PQAQ   Does the article present the relationship with the sponsor of the 
study? 
  
 Does the article indicate that the authors had independent control 
over the methods and right to publish? 
  
* Typically high quality if information was available regardless of whether conflicts of interest were reported or not. 
** Typically high quality if active statement that no conflicts of interest were reported and low quality if conflicts of interest 
were reported or no information was available. 
*** Typically high quality if some procedural elements were included in study minimising influence from conflicts of 
interest or if only conflicts of interest judged to be minor were reported.  
 
 
What is new? 
 
Key findings 
•  We identified no appraisal tool designed specifically to address conflicts of interests 
in medical research studies. Twenty-seven tools included 1-2 short items mainly 
focusing on whether conflicts of interest information was available or if any conflicts 
of interest were reported. There was little guidance on assessing how conflicts of 
interest may influence studies.  
•  In a small sample of 30 top medical journals more than half had no explicit policies 
on managing conflicts of interest in journal papers beyond standard disclosure 
practices. Journals with policies to manage conflicts of interest mainly placed some 
form of restriction on non-research papers, publishing only those where authors did 
not have financial conflicts of interest.  
 
What this adds to what is known? 
•  Conflicts of interest are considered important, but the focus in both appraisal tools 
and journals is on how conflicts of interest are disclosed; not on how conflicts of 
interest may influence studies or how journal policies may minimise such influence. 
 
What is the implication, what should change now? 
•  There is need for more comprehensive evidence-based guidance for addressing 
conflicts of interest in research studies. 
•  The International Committee of Medical Journal Editors and medical journals could 
consider developing, revising and harmonising explicit policies on managing 
conflicts of interest in their journal papers. 
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